What does it take to move from concept to commercial vaccine manufacturing at speed without compromising quality or compliance? In this conversation, leaders from Alfasigma’s CDMO arm, Morpho, share a detailed look at how they approached a complex vaccine technology transfer, from facility upgrades to regulatory approval. The discussion offers a grounded perspective on execution, coordination, and capability building in today’s evolving CDMO landscape. This podcast explores: • The role of facility design, sterile manufacturing, and cold chain expansion • Why flexibility in equipment and formats matters for biological products • Approaches to contamination control and aseptic processing • Coordinating engineering, quality, and regulatory teams under tight timelines • What this project reveals about broader CDMO trends, from personalization to speed and sustainability

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related